

069331

CONVENTION

AUSTRALIA

Patents Act 1990

NOTICE OF ENTITLEMENT

We, **BRISTOL-MYERS SQUIBB COMPANY** of 345 Park Avenue, New York, New York 10154, United States of America state the following in connection with Australian Application No. 18878/92:

1. We are the nominated person.
2. The nominated person is the assignee of the actual inventors.
3. The nominated person is the assignee of the applicants of the basic application listed in the declaration under Article 8 of the PCT.
4. The basic application is the application first made in a Convention country in respect of the invention.

Dated: 8 September 1993

By **PHILLIPS ORMONDE & FITZPATRICK**
Patent Attorneys for the Applicant
By: *David B Fitzpatrick*

.....

To: The Commissioner of Patents

PHILLIPS ORMONDE & FITZPATRICK
367 Collins Street
Melbourne, Australia, 3000

Our Ref: 340402

i925x



AU9218878

(12) PATENT ABRIDGMENT (11) Document No. AU-B-18878/92
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 669331

(54) Title
TGF-BETA 1/BETA 2: A NOVEL CHIMERIC TRANSFORMING GROWTH FACTOR-BETA

International Patent Classification(s)
(51)⁵ A61K 037/02 C07K 013/00 A61K 039/395

(21) Application No. : 18878/92 (22) Application Date : 13.03.92

(87) PCT Publication Number : WO92/16228

(30) Priority Data

(31) Number	(32) Date	(33) Country
669171	14.03.91	US UNITED STATES OF AMERICA

(43) Publication Date : 21.10.92

(44) Publication Date of Accepted Application : 06.06.96

(71) Applicant(s)
BRISTOL-MYERS SQUIBB COMPANY

(72) Inventor(s)
ANTHONY F. PURCHIO; LINDA MADON; JUNE MERWIN

(74) Attorney or Agent
PHILLIPS ORMONDE & FITZPATRICK 167 Collins Street, MELBOURNE VIC 3000

(56) Prior Art Documents
AU 45882/89 A61K

(57) Claim

1. A chimeric transforming growth factor $\beta 1/\beta 2$.
2. A chimeric transforming growth factor $\beta 1/\beta 2$ consisting of the amino acid sequence as given in figure 1A - 1D.
3. A chimeric transforming growth factor 5β consisting of amino acids 279 - 390 as given in figure 1C- 1D.

RECTED
STION *

PCT

pages 1-30, description, replaced by new pages 1-33; page 31, claims, replaced by new page 34; pages 1/11-11/11, drawings, replaced by new pages 1/12-12/12; due to late transmittal by the receiving Office



188 78/92.

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/24, C07K 13/00	A1	(11) International Publication Number: WO 92/16228 (43) International Publication Date: 1 October 1992 (01.10.92)
(21) International Application Number: PCT/US92/01993 (22) International Filing Date: 13 March 1992 (13.03.92) (30) Priority data: 669,171 14 March 1991 (14.03.91) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/ US]; 345 Park Avenue, New York, NY 10154 (US). (72) Inventors: PURCHIO, Anthony, F. ; 801 33rd East, Seattle, WA 98112 (US). MADISEN, Linda ; 5255 South Brigh- ton, Seattle, WA 98118 (US). MERWIN, June ; 19 Kenil- worth Drive, Clinton, CT 06413 (US).		(74) Agent: MISROCK, S., Leslie; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (Eu- ropean patent), NO, SE (European patent). Published <i>With international search report.</i> 669331
(54) Title: TGF- β 1/ β 2: A NOVEL CHIMERIC TRANSFORMING GROWTH FACTOR-BETA (57) Abstract The present invention relates to the production of large quantities of a novel chimeric TGF- β , termed TGF- β 1/ β 2, by eu- caryotic host cells transfected with recombinant DNA vectors containing the TGF- β 1/ β 2 precursor coding sequence controlled by expression regulatory elements. Simian TGF- β 1 cDNA (Sharples et al., 1987, DNA 6:239-244) was modified so that the nucleo- tides encoding amino acid residue numbers 9-13, 17, 19, 25 and 26 of the mature TGF- β 1 sequence were hanged to the nucleo- tides encoding the corresponding amino acids of the mature TGF- β 2 structure. Simian codon usage was maintained. The chimer- ic TGF- β 1/ β 2 of the invention induces effects on the proliferation of vascular endothelial cells equivalent to those induced by TGF- β 1 (see Section 7., <i>et seq.</i>).		

- 1 -

TGF- β 1/ β 2: A NOVEL CHIMERIC
TRANSFORMING GROWTH FACTOR-B

1. INTRODUCTION

5 The present invention relates to a novel chimeric transforming growth factor-beta termed TGF- β 1/ β 2 (or TGF- β 5), to nucleotide sequences and expression vectors encoding TGF- β 1/ β 2, and to methods for the
10 production of TGF- β 1/ β 2. The invention is exemplified by the production and secretion of TGF- β 1/ β 2 by CHO cells transfected with expression vectors encoding a chimeric TGF- β 1/ β 2 precursor gene. The chimeric gene product possesses TGF- β biological activity.

15 2. BACKGROUND OF THE INVENTION

 Transforming growth factor-beta (TGF- β) is a member of a recently described family of polypeptides that regulate cellular differentiation and
20 proliferation. Other members of this family include Mullerian inhibitory substance (Cate et al., 1986, Cell 45:685-698), the inhibins (Mason et al., 1985, Nature 318:659-663) and a protein predicted from a transcript of the decapentaplegic gene complex of
25 Drosophila (Padgett et al., 1987, Nature 325:81-84).

 Four types of TGF- β have been identified and designated TGF- β 1, TGF- β 2, TGF- β 1.2, and TGF- β 3. The first described type, TGF- β 1, consists of two identical disulfide linked subunits having molecular
30 weights of 13,000 (Assoian et al., 1983, J. Biol. Chem. 258:7155-7160; Frolik et al, 1983, Proc. Natl. Acad. Sci. USA 80:3676-3680; Frolik et al., 1984, J. Biol. Chem. 260:10995-11000). It has been purified from several tissue sources including placenta (Frolik
35 et al., 1983, Nature 325:81-84), blood platelets (Childs et al., 1982, Proc. Natl. Acad. Sci. USA

- 2 -

79:5312-5316; Assoian et al., 1983, J. Biol. Chem. 258:7155-7160) kidney (Roberts et al., 1983, Biochemistry 22:5692-5698), and demineralized bone (Seyedin et al., 1985, Proc. Natl. Acad. Sci. USA 82:119-123). cDNA clones coding for human (Derynck et al., 1985, Nature 316:701-705), mouse (Derynck et al., 1986, J. Biol. Chem. 261:4377-4379) and simian (Sharples et al., 1987, DNA 6:239-244) TGF- β 1 have been isolated. DNA sequence analysis of these clones indicates that TGF- β 1 is synthesized as a large precursor polypeptide, the carboxy terminus of which is cleaved to yield the mature TGF- β monomer. Strong sequence homology has been found throughout the TGF- β 1 precursor protein from all of the above sources.

In the presence of 10% serum and epidermal growth factor, TGF- β 1 promotes the anchorage independent growth of normal rat kidney fibroblasts (Roberts et al., 1981, Proc. Natl. Acad. Sci. USA 78:5339-5343; Roberts et al., 1982, Nature 295:417-419; Twardzik et al., 1985, J. Cell. Biochem. 28:289-297); in the presence of 10% serum alone, it is able to induce colony formation of AKR-2B fibroblasts (Tucker et al., 1983, Cancer Res. 43:1518-1586). TGF- β 1 has also been shown to cause fetal rat muscle mesenchymal cells to differentiate and produce cartilage specific macromolecules (Seyedin et al., 1986, J. Biol. Chem. 261:5693-5695).

In contrast to its effect on cell proliferation, TGF- β 1 purified from human platelets has been shown to inhibit the growth of certain cells in culture (Tucker et al., 1984, Science 226:705-707). TGF- β 1 has also been shown to inhibit the growth of several human cancer cell lines (Roberts et al., 1985, Proc. Natl. Acad. Sci. USA 82:119-123). This inhibitory/stimulatory effect of TGF- β 1 may depend on

- 3 -

several factors including cell type and the physiological state of the cells (for review see Sporn et al., 1986, Science 233:532-534).

TGF- β 2, like TGF- β 1, is a polypeptide of
5 molecular weight 26,000 composed of two identical
13,000-dalton subunits which are disulfide linked
(Chieffetz et al., 1987, Cell 48:409-415; Ikeda et al.,
1987, Biochemistry 26:2406-2410) and has been isolated
from bovine demineralized bone (Seydin et al., 1987,
10 J. Biol. Chem. 262:1946-1949), porcine platelets
(Chieffetz et al., 1987, 48:409-415), a human prostatic
adenocarcinoma cell line, PC-3 (Ikeda et al., 1987,
Biochemistry 26:2406-2410), and a human glioblastoma
cell line (Wrann et al., 1987, EMBO 6:1633-1636).
15 cDNA clones coding for human and simian TGF- β 2 have
been isolated (Madisen et al., 1988, DNA 7:1-8; Webb
et al., 1988, DNA 7:493-497). The mature TGF- β 2
monomer is cleaved from one of two larger precursor
polypeptides, the mRNAs of which may arise via
20 differential splicing (Webb et al., 1988, DNA 7:493-
497).

TGF- β 1 and TGF- β 2 share 71% amino acid sequence
identity in their mature regions, and 41% identity in
their precursor structures. TGF- β 3, the amino acid
25 sequence of which has very recently been deduced from
cDNA clones, appears to contain a C-terminal 112 amino
acid sequence with about 80% homology to the mature
monomers of TGF- β 1 and TGF- β 2 (Dijke et al., 1988,
Proc. Natl. Acad. Sci. USA 85:4715-4719). TGF- β 1.2 is
30 a heterodimeric form comprising a β 1 and β 2 subunit
linked by disulfide bonds (Chieffetz et al., 1987, Cell
48:409-415).

35

SUBSTITUTE SHEET

- 4 -

2.1 INTRACELLULAR PROCESSING OF TGF- β 1

The amino portion of the precursor region of TGF- β 1 from human, rodent and simian sources show a high
5 degree of homology (Derynck et al., 1985, Nature 316:701-705; Derynck et al., 1986, J. Biol. Chem. 261:4377-4379; Sharples et al., 1987, DNA 6:239-244), suggesting an important biological function may be associated with this part of the molecule. Recent
10 studies demonstrating that this portion of the TGF- β 1 precursor is glycosylated and phosphorylated support this contention since one might assume that a cell would not go through the expense of performing these secondary modifications were it not for a specific
15 function (Brunner et al., 1988, Mol. Cell. Biol. 8:2229-2232). These modifications may be important for dimerization of the precursor or for directing its movement out of the cell. There is evidence which suggests that glycosylation of the precursor is
20 involved in the transport of mature TGF- β 1 out of the cell (Purchio et al., 1988, J. Biol. Chem. 263:14211-14215).

The existence of what may either be intermediate precursor complexes involved in processing or
25 expression artifacts in CHO cells expressing the simian TGF- β 1 gene has been reported (Gentry et al., 1988, Mol. Cell. Biol. 8:4162-4168 press; Gentry et al., 1987, Mol. Cell. Biol. 7:3418-3427). These studies revealed that the TGF- β 1 precursor synthesized
30 by transfected CHO cells consists of pro-TGF- β 1, mature TGF- β 1, and the pro region of the precursor interlinked by disulfide bonds. Such disulfide-linked precursor complexes have also been observed in isolated latent forms of TGF- β 1 (Miyazano et al.,
35

- 5 -

1988, J. Cell. Biochem. Suppl. 12(A):200; Wakefield et al., 1987, J. Biol. Chem. Suppl. 11(A):46).

Gentry et al. (Gentry et al., 1988, Mol. Cell. Biol., 8:4162-4168) have proposed the following scheme
5 for the processing of pre-pro-TGF- β 1 in transfected CHO cells. (The amino acid position numbers referred to are from the published sequence of simian TGF- β 1 (Sharples et al., 1987, DNA 6:239-244)). According to
10 this proposed scheme, the first step involves signal peptide cleavage at the Gly-29/Leu-30 peptide bond. This cleavage event most likely occurs co-translationally during transit of the precursor through the rough endoplasmic reticulum membrane (Blobel and Dobberstein, 1975, J. Cell. Biol. 67:835-
15 851; Walter et al., 1984, Cell 38:5-8). Following cleavage of the signal peptide, core glycosylation units (Rothman et al., 1978, Cell 15:1447-1454) are added to pro-TGF- β 1 at each of three predicted N-glycosylation sites located at Asn-82, Asn-136 and
20 Asn-176. The core glycosylated pro-TGF- β 1 is then sequentially processed during transit through the Golgi to yield a phosphorylated glycoprotein containing complex, sialated oligosaccharides. At some stage during synthesis or transit, proteolytic
25 cleavage at the dibasic residue and disulfide isomerization occurs, releasing mature TGF- β 1.

In another recent study, mannose-6-phosphate was identified in the TGF- β 1 precursor. Mannose-6-phosphate, a phosphorylated sugar analog, appears to
30 play a fundamental role in the targeted transport and intercellular exchange of lysosomal enzymes (von Figura, 1986, Ann. Rev. Biochem. 55: 167-193). Specific receptors which recognize the mannose-6-phosphate residues of lysosomal enzymes have been
35 identified and are essential components of the

- 6 -

transport system. Secreted lysosomal proteins containing mannose-6-phosphate have been identified in the conditioned medium of tissue culture cells (Gal and Gottesman, 1986, J. Biol. Chem. 261:1760-1765; Capony et al., 1981, J. Cell. Biol. 104:253-262; Baumbach et al., 1984, Proc. Natl. Acad. Sci. USA 81:2985-2989; Sahagian and Gottesman, 1982, J. Biol. Chem. 257:11145-11150). It is possible that the mannose-6-phosphate residues of the TGF- β 1 precursor may direct pro-TGF- β 1 to lysosomes for proteolytic processing to yield mature TGF- β 1. Alternatively, the mannose-6-phosphate residues may function to target the cleaved TGF- β 1 precursor to lysosomes for degradation.

15

3. SUMMARY OF THE INVENTION

The present invention relates to the production of large quantities of a novel chimeric TGF- β , termed TGF- β 1/ β 2, by eucaryotic host cells transfected with recombinant DNA vectors containing the TGF- β 1/ β 2 precursor coding sequence controlled by expression regulatory elements. Simian TGF- β 1 cDNA (Sharples et al., 1987, DNA 6:239-244) was modified so that the nucleotides encoding amino acid residue numbers 9-13, 17, 19, 25 and 26 of the mature TGF- β 1 sequence were changed to the nucleotides encoding the corresponding amino acids of the mature TGF- β 2 structure. Simian codon usage was maintained.

~~Expression vectors encoding the chimeric TGF- β 1/ β 2 precursor under the regulatory control of Simian Virus 40 (SV 40) expression regulatory elements were constructed and used to transfect Chinese Hamster ovary (CHO) cells. CHO transfectants which synthesize and secrete high levels of mature TGF- β 1/ β 2 were obtained. TGF- β 1/ β 2 expression was amplified with~~



SUBSTITUTE SHEET

6A

The present invention also relates to a novel chimeric transforming growth factor 5β consisting of amino acids 279 to 390 as given in figure 1C - 1D, pharmaceutical compositions comprising this molecule and use of this molecule in inhibiting the proliferation of vascular endothelial cells and in inducing smooth muscle cell migration.

- 5 In a further aspect the present invention also relates to a pharmaceutical composition comprising an antibody to chimeric transforming growth factor 5β consisting of amino acids 279 to 390 as given in Figure 1C - 1D for use in inhibiting microvascular cell neovascularisation.

- 10 Expression vectors encoding the chimeric TGF- $\beta 1/\beta 2$ precursor under the regulatory control of Simian Virus 40 (SV 40) expression regulatory elements were constructed and used to transfect Chinese Hamster ovary (CHO) cells. CHO transfectants which synthesise and secrete high levels of mature TGF- $\beta 1/\beta 2$ were obtained. TGF- $\beta 1/\beta 2$ expression was amplified with



- 7 -

methotrexate and amplified transfectants secreted as much as 1mg/L mature TGF- β 1/ β 2. Acidification of the conditioned media of the CHO transfectants resulted in maximal levels of bioactive TGF- β 1/ β 2. It is believed
5 that the high levels of mature TGF- β 1/ β 2 secreted by the transfected CHO cells results from an unusual efficiency in the proteolytic processing of the chimeric precursor protein. Such increased processing efficiency may, in turn, result from structural
10 characteristics affected by applicants' combination of the TGF- β 1 and TGF- β 2 amino acid sequences in the amino-terminal domain of the mature TGF- β structure.

The chimeric TGF- β 1/ β 2 of the invention induces effects on the proliferation of vascular endothelial
15 cells equivalent to those induced by TGF- β 1 (see Section 7., et seq.).

4. DESCRIPTION OF THE FIGURES

FIG. 1. Nucleotide and deduced amino acid
20 sequence of the TGF- β 1/ β 2 hybrid protein encoded by expression plasmid p5 β /dhfr.

FIG. 2. Bioactivity of conditioned media from 5 β 41,2.5 cells. Bioactivity was measured by the growth inhibition assay of CCL-64 mink lung epithelial
25 cells. (A) Serum-free media conditioned by 5 β 41,2.5 cells for 24 hours was dialyzed against 0.2 M acetic acid and assayed as described in Section 6.1.3., infra. (B) Standard growth inhibition curve for TGF- β 1.

30 FIG. 3. Immunoblot analysis of proteins secreted by 5 β 41,2.5 cells. 5 β 41,2.5 cells were grown to confluence; media was dialyzed against 0.2 M acetic acid and assayed by immunoblotting under nonreducing (lane 1) or reducing (lane 2) conditions with anti-
35 TGF- β 1₃₆₉₋₃₈₁ as described in Section 6.1.5., infra.

SUBSTITUTE SHEET

- 8 -

FIG. 4. Effect of various TGF- β s on vascular endothelial cells. Two-dimensional, five-day vascular cell cultures were grown in DME plus 10% FCS (control) with additions of TGF- β 1, TGF- β 2, both at 0.5 ng/ml, or TGF-5 β at concentrations of 0.05, 0.5 or 5.0 ng/ml. (A) BAEC; (B) BASMC; (C) RFC. In all cases the TGF-5 β hybrid molecule mimicked the TGF- β 1 isoform.

FIG. 5. Effect of various TGF- β s on vascular cell migration. Migrating aortic endothelial and smooth muscle cells were treated with TGF- β 1 and TGF- β 2 at 0.5 ng/ml and TGF-5 β at concentrations of 0.05, 0.5 or 5.0 ng/ml. TGF-5 β mimicked the TGF- β 1 response induced on BASMCs by increasing migratory rates, while the opposite effect was seen when using large vessel endothelial cells. TGF- β 2 elicited no effect on either cell type.

FIG. 6. Angiogenic response induced by various TGF- β s. Three-dimensional RFC cultures were viewed with Hoffman interference microscopy to analyze angiogenic responses elicited by TGF- β 1, TGF- β 2, and TGF-5 β . Four-day, 3-D small vessel endothelial cultures were cryosectioned at 8 μ m and acetone fixed. Control cultures (A) were grown in DME plus 10% FCS. Treated cultures included: (B) TGF- β 1 (0.5 ng/ml); (C) TGF- β 2 (0.5 ng/ml); and TGF-5 β at (D) 0.05 ng/ml; (E) 0.5 ng/ml and (F) 5.0 ng/ml. TGF- β 1 evokes complex, branching tubular structures, while the control cultures showed minimal tube formation. TGF-5 β at 0.05 ng/ml gave an indication of commencing neovascularization, while 0.5 ng/ml of the hybrid molecule stimulated an angiogenic response equivalent to the TGF- β 1 isoform. The highest concentration of TGF-5 β appears to cause a slight decrease in the amount of complex branching structures which had been shown before using TGF- β 1. TGF- β 2 required a 10-fold

- 9 -

increase in concentration (5.0 ng/ml) in order to match the neovascularization induced by TGF- β 1 and TGF- β 2 at 0.5 ng/ml. Arrows indicate tubular formations by RFCs. Magnification = 100 X.

5

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to TGF- β 1/ β 2, to nucleotide sequences encoding TGF- β 1/ β 2 and the TGF- β 1/ β 2 precursor, and to the production of TGF- β 1/ β 2 by
10 recombinant DNA methods. TGF- β 1/ β 2, a novel chimeric transforming growth factor-beta, is biologically active in the standard assay used to measure TGF- β 1 bioactivity and is immunoreactive with TGF- β 1-specific antibodies. A chimera structurally comprising a
15 combination of TGF- β 1 and TGF- β 2 amino acid sequences, the TGF- β 1/ β 2 of the invention is likely to carry a novel portfolio of biological activities, some of which may be similar or nearly identical to those exhibited by its parent molecules while others may be
20 unique to TGF- β 1/ β 2. With regard to those bioactivities which are similar or nearly identical to those of TGF- β 1 or TGF- β 2, this new factor may provide a more effective means of inducing corresponding biological responses and its use may therefore be a
25 desirable alternative to TGF- β 1 and TGF- β 2 in various medical applications envisioned for the TGF- β s. Such applications include but are not limited to inducing or accelerating cell proliferation and differentiation and, inhibiting cell division. Thus TGF- β 1/ β 2 may
30 find uses in, for example, treating cancer and promoting wound healing.

The method of the invention may be divided into the following stages solely for the purposes of description: (a) generation of the coding sequence
35 for the TGF- β 1/ β 2 precursor; (b) construction of an

- 10 -

expression vector which will direct the expression of the TGF- β 1/ β 2 coding sequence; (c) transfection of appropriate host cells which are capable of replicating, expressing the gene and processing the gene product to produce the mature form of TGF- β 1/ β 2 and/or TGF- β 1/ β 2 precursors; and (d) identification and purification of the TGF- β 1/ β 2 precursors and the mature, biologically active TGF- β 1/ β 2.

Once a transfectant is identified that expresses high levels of TGF- β 1/ β 2 precursors and/or mature TGF- β 1/ β 2, the practice of the method of the invention involves the expansion of that clone and isolation of the gene product expressed.

The method of the invention is demonstrated herein, by way of examples in which simian TGF- β 1 precursor cDNA (Sharples et al., 1987, DNA 6:239-244) is modified so that the nucleotides encoding amino acid residue numbers 9-13, 17, 19, 25 and 26 of the mature simian TGF- β 1 sequence are changed to the nucleotides encoding the corresponding amino acids in the mature TGF- β 2 structure, while maintaining simian codon usage. The resulting chimeric TGF- β 1/ β 2 precursor coding sequence is then used to construct expression vectors which are capable of directing the synthesis of the mature TGF- β 1/ β 2 product.

The effects of TGF- β 1/ β 2 on the proliferation, migration and angiogenesis of vascular endothelial cells have been examined in vitro (section 7., et seq.) and appear to closely parallel those induced by TGF- β 1 but not TGF- β 2.

The various aspects of the method of the invention are described in more detail in the subsections below and in the examples that follow.

35

- 11 -

5.1 GENERATION OF THE CHIMERIC TGF- β 1/ β 2 CODING SEQUENCE

The nucleotide coding sequence for the chimeric
5 TGF- β 1/ β 2 is depicted in FIG. 1. In the practice of
the method of the invention, this nucleotide sequence
or its functional equivalent can be used to generate
the recombinant molecules which will direct the
expression of the TGF- β 1/ β 2 product. Due to the
10 degeneracy of the nucleotide coding sequences, other
DNA sequences as depicted in FIG. 1 may be used in the
practice of the present invention. Such alterations
of the nucleotide sequence of FIG. 1 include
deletions, additions or substitutions of different
15 nucleotide residues resulting in a sequence that
encodes the same or a functionally equivalent gene
product. The gene product may contain deletions,
additions or substitutions of amino acid residues
within a sequence, which result in a silent change
20 thus producing a bioactive product. Such amino acid
substitutions may be made on the basis of similarity
in polarity, charge, solubility, hydrophobicity,
hydrophilicity and/or the amphipathic nature of the
residues involved. For example, negatively charged
25 amino acids include aspartic acid and glutamic acid;
positively charged amino acids include lysine and
arginine; amino acids with uncharged dipolar head
groups or nonpolar head groups having similar
hydrophilicity values include the following: leucine,
30 isoleucine, valine; glycine, alanine; asparagine,
glutamine; serine, threonine; phenylalanine, tyrosine.

The nucleotide sequence for simian TGF- β 1 may be
obtained from simian cell sources (Sharples et al.,
1989, DNA 6:239-244). The nucleotide sequence of the
35 chimeric TGF- β 1/ β 2 in FIG. 1 may be prepared by
methods known in the art including but not limited to

- 12 -

the use of DNA restriction enzymes, synthetic oligonucleotides, and DNA ligases. Alternatively, the coding sequence of FIG. 1 may be synthesized in whole or in part using chemical methods well known in the art.

In a specific embodiment of the invention, the coding sequence for simian TGF- β 1 was obtained from a full length cDNA clone obtained from an African green monkey cell line, BSC-40 (Sharples et al., 1987, supra). The coding sequence of chimeric TGF- β 1/ β 2 depicted in FIG. 1 was then derived from the simian TGF- β 1 cDNA by removing and replacing the coding sequences of amino acid residue numbers 9, 10, 11, 12, 13, 17, 19, 25 and 26 of the mature TGF- β 1 molecule with the coding sequences for amino acid residue numbers 9, 10, 11, 12, 13, 17, 19, 25 and 26 of the mature TGF- β 2 molecule (Madisen et al., 1988, DNA 7:1-8) using gene construction techniques.

5.2 CONSTRUCTION OF EXPRESSION VECTORS CONTAINING THE CHIMERIC TGF- β 1/ β 2 CODING SEQUENCE

In order to express biologically active, mature TGF- β 1/ β 2, an expression vector/host system should be chosen which provides not only for high levels of transcription and translation but for the correct processing of the gene product. This is especially important when employing the entire coding sequence of the chimeric TGF- β 1/ β 2 precursor in the expression constructs because, like TGF- β 1 and TGF- β 2, the mature chimeric TGF- β 1/ β 2 is believed to be released from a precursor molecule or complex of molecules via cellular processing events. In addition, an expression/host cell system which provides for secretion of the product may be desirable.

In particular, it appears that mature TGF- β 1/ β 2 is a disulfide linked homodimer of 112 amino acids per

- 13 -

subunit formed by cellular processing events believed to be similar to those which form mature TGF- β 1 and TGF- β 2. The TGF- β 1/ β 2 precursor has three potential N-glycosylation sites in its pro domain (Sharples et al., 1987, DNA 6:239-244). Studies involving TGF- β 1 have determined that N-glycosylation and phosphorylation in the pro domain of TGF- β 1 occurs in transfected CHO cells, implicating an important functional role for the precursor in the cellular synthesis and release or secretion of the mature molecule (Brunner et al., 1988, Mol. Cell. Biol. 8:2229-2232). The presence of mannose-6-phosphate in the TGF- β 1 precursor also supports the hypothesis that the precursor has independent functional activity (Purchio et al., 1988, J. Biol. Chem. 263:14211-14215). Since the chimeric TGF- β 1/ β 2 precursor contains the simian TGF- β 1 pro domain, applicants believe it likely that the TGF- β 1/ β 2 precursor is functionally active and important to the correct processing the mature TGF- β 1/ β 2 molecule. Thus, the ability of a host cell used in the expression system to correctly express and process chimeric TGF- β 1/ β 2 is important to the production of a mature, bioactive product.

In a specific embodiment described herein, mature bioactive TGF- β 1/ β 2 is successfully produced using simian virus 40 (SV40) expression control elements in a Chinese Hamster Ovary (CHO) host cell system. However, a variety of other animal host/expression vector systems (i.e., vectors which contain the necessary elements for directing the replication, transcription and translation of the TGF- β 1/ β 2 coding sequence in an appropriate host cell) may be utilized equally well by the skilled artisan. These include, but are not limited to, virus expression

- 14 -

vector/mammalian host cell systems (e.g.,
cytomegalovirus, vaccinia virus, adenovirus, and the
like); insect virus expression vector/insect cell
systems (e.g., baculovirus); or nonviral promoter
5 expression systems derived from the genomes of
mammalian cells (e.g., the mouse metallothionein
promoter).

The expression elements of these vectors vary in
their strength and specificities. Depending on the
10 host/vector system utilized, any one of a number of
suitable transcription and translation elements may be
used. For instance, when cloning in mammalian cell
systems, promoters isolated from the genome of
mammalian cells, (e.g. mouse metallothionein promoter),
15 or from viruses that grow in these cells, (e.g.
vaccinia virus 7.5K promoter) may be used. Promoters
produced by recombinant DNA or synthetic techniques
may also be used to provide for transcription of the
inserted sequences.

20 Specific initiation signals are also required for
sufficient translation of inserted protein coding
sequences. These signals include the ATG initiation
codon and adjacent sequences. For example, in cases
where only a portion of the TGF- β 1/ β 2 coding sequence
25 is inserted, exogenous translational control signals,
including the ATG initiation codon must be provided.
Furthermore, the initiation codon must be in phase
with the reading frame of the TGF- β 1/ β 2 coding
sequences to ensure translation of the entire insert.
30 These exogenous translational control signals and
initiation codons can be of a variety of origins, both
natural and synthetic. The efficiency of expression
may be enhanced by the inclusion of transcription
attenuation sequences, enhancer elements, and the
35 like.

- 15 -

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing the TGF- β 1/ β 2 coding sequence and appropriate

5 transcriptional/translational control signals. These methods may include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombinations (genetic recombination).

10 In cases where an adenovirus is used as an expression vector, the TGF- β 1/ β 2 coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro
15 or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing chimeric TGF- β 1/ β 2 in infected hosts. Similarly, the vaccinia 7.5K promoter
20 may be used.

An alternative expression system which could be used to express TGF- β 1/ β 2 is an insect system. In one such system, Autographa californica nuclear polyhidrosis virus (AcNPV) is used as a vector to
25 express foreign genes. The virus grows in Spodoptera frugiperda cells. The TGF- β 1/ β 2 coding sequence may be cloned into non-essential regions (for example, the polyhedrin gene) of the virus and placed under the control of an AcNPV promoter (for example, the
30 polyhedrin promoter). Successful insertion of the TGF- β 1/ β 2 coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat encoded by the polyhedrin gene).
35 These recombinant viruses are then used to infect

SUBSTITUTE SHEET

- 16 -

Spodoptera frugiperda cells in which the inserted gene is expressed.

In addition, a host cell strain may be chosen which modulates the expression of the inserted
5 sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers, (e.g. zinc and cadmium ions for metallothionein promoters). Therefore, expression of
10 the genetically engineered TGF- β 1/ β 2 may be controlled. This is important if the protein product of the cloned foreign gene is lethal to host cells. Furthermore, post-translational modifications such as glycosylation, and processing events such as
15 proteolytic cleavage of protein products, may be important to the functionality of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cell lines or
20 host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.

In a specific embodiment of the invention, an expression vector containing the TGF- β 1/ β 2 coding
25 sequence in tandem with the mouse dihydrofolate reductase gene (dhfr) under the control of SV40 regulatory sequences is constructed and used to transfect dhfr-deficient CHO cells. CHO transfectants expressing the dhfr phenotype are isolated by
30 propagation in selective media. To increase the level of expression of TGF- β 1/ β 2, transfectants may be exposed to increasing concentrations of methotrexate in order to isolate clones transcribing amplified levels of TGF- β 1/ β 2 mRNA. TGF- β 1/ β 2 mRNA levels may
35 be assayed at various stages of amplification by

- 17 -

solution hybridization (Uhler et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:1300-1304).

5 5.3 IDENTIFICATION OF TRANSFECTANTS EXPRESSING
 CHIMERIC TGF- β 1/ β 2

 The host cells which contain the TGF- β 1/ β 2 coding sequence and which express the biologically active, mature product may be identified by at least four general approaches: (a) DNA-DNA hybridization; (b) the
10 presence or absence of "marker" gene functions; (c) assessing the level of transcription as measured by the expression of TGF- β 1/ β 2 mRNA transcripts in the host cell; and (d) detection of the mature gene product as measured by immunoassay and, ultimately, by
15 its biological activities.

 In the first approach, the presence of the TGF- β 1/ β 2 coding sequence inserted in the expression vector can be detected by DNA-DNA hybridization using probes comprising nucleotide sequences that are
20 homologous to the TGF- β 1/ β 2 coding sequence substantially as shown in FIG. 1, or portions or derivatives thereof.

 In the second approach, the recombinant expression vector/host system can be identified and
25 selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, resistance to methotrexate, transformation phenotype, occlusion body formation in baculovirus, etc.). For example, if the
30 TGF- β 1/ β 2 coding sequence is inserted within a marker gene sequence of the vector, recombinants containing the TGF- β 1/ β 2 coding sequence can be identified by the absence of the marker gene function. Alternatively, a marker gene can be placed in tandem with the TGF- β 1/ β 2
35 sequence under the control of the same or different promoter used to control the expression of the TGF-

- 18 -

$\beta 1/\beta 2$ coding sequence. Expression of the marker in response to induction or selection indicates expression of the TGF- $\beta 1/\beta 2$ coding sequence.

In the third approach, transcriptional activity
5 for the TGF- $\beta 1/\beta 2$ coding region can be assessed by hybridization assays. For example, polyadenylated RNA can be isolated and analyzed by Northern blot using a probe homologous to the TGF- $\beta 1/\beta 2$ coding sequence or particular portions thereof. Alternatively, total
10 nucleic acids of the host cell may be extracted and assayed for hybridization to such probes.

In the fourth approach, the expression of the mature protein product can be assessed immunologically, for example by Western blots,
15 immunoassays such as immunoblotting, radioimmunoprecipitation, enzyme-linked immunoassays, and the like. The ultimate test of the success of the expression system, however, involves the detection of the biologically active TGF- $\beta 1/\beta 2$ gene product. Where
20 the host cell secretes the gene product, the cell free media obtained from the cultured transfectant host cell may be assayed for TGF- $\beta 1/\beta 2$ activity. Where the gene product is not secreted, cell lysates may be assayed for such activity. In either case, biological
25 assays such as the growth inhibition assay described herein or the like may be used.

Once a clone producing high levels of mature TGF- $\beta 1/\beta 2$ is identified, the clone may be expanded and the TGF- $\beta 1/\beta 2$ may be purified using techniques well known
30 in the art. Such methods include immunoaffinity purification, chromatographic methods including high performance liquid chromatography, and the like.

35

- 19 -

5.4 IMPROVED METHOD FOR PRODUCING MATURE TGF- β 1/ β 2

In a specific embodiment of the invention, the TGF- β 1/ β 2 precursor may be modified by eliminating the amino acid cysteine at position 33 (CYS-33) of FIG. 1 and replacing it with serine. This modification may be introduced at the DNA level using site directed mutagenesis. COS cells transfected with plasmids encoding the TGF- β 1 precursor gene so modified ultimately secrete between three and five times more mature TGF- β 1 than do CHO cells expressing the unmodified precursor gene. It is believed that this modification prevents the formation of certain disulfide-linked precursor complexes in the transfected COS cells and therefore allows for the secretion of more mature TGF- β .

6. EXAMPLE: PRODUCTION OF TGF- β 1/ β 2 BY EXPRESSION IN CHINESE HAMSTER OVARY CELLS

A recombinant plasmid encoding TGF- β 1 precursor in which amino acids 9, 10, 11, 12, 13, 17, 19, 25 and 26 of the mature TGF- β 1 sequence were replaced by the corresponding amino acids of the mature TGF- β 2 sequence was constructed. Specifically, amino acid 9 of mature TGF- β 1 (serine) was replaced by arginine, amino acid number 10 (serine) was replaced by asparagine, amino acid number 11 (threonine) was replaced by valine, amino acid number 12 (glutamic acid) was replaced by glutamine, amino acid number 13 (lysine) was replaced by aspartic acid, amino acid number 17 (valine) was replaced by leucine, amino acid number 19 (glutamine) was replaced by proline, amino acid number 25 (arginine) was replaced by lysine and amino acid number 26 (lysine) was replaced by arginine. The construct was used to transfect CHO

- 20 -

cells. Transfectants which produced and secreted a mature, bioactive, chimeric TGF- β 1/ β 2 were isolated.

6.1 MATERIALS AND METHODS

5

6.1.1 DNA TRANSFECTIONS

Approximately 24 hours after seeding 10^6 dhfr-deficient CHO cells onto 100 mm dishes, the cultures were transfected with 1 μ g of NdeI linearized p5 β /dhfr
10 plasmid and 19 μ g of calf thymus DNA as carrier as a calcium phosphate precipitate (Wigler, M., et al., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:1373-1376). Briefly, 20 μ g of plasmid plus carrier DNA was added to 1 ml of 250 mM sterile CaCl₂. The DNA solution (1
15 ml) was added dropwise to a 1 ml portion of 2X HEPES solution (280 mM NaCl, 50 mM HEPES, 1.5 mM sodium phosphate, pH 7.1) while bubbling and the mixture was allowed to sit on ice for 30 minutes. The precipitate was then dispersed dropwise over the cells containing
20 10 ml of F12 media (Gibco). After incubation at 37°C for 4 hours, the media was removed and replaced with 10 ml of F12 media containing 25% glycerol for 90 seconds at room temperature. Cells were rinsed once with 20 ml of F12 media and incubated in the
25 nonselective F12 media (20 ml) for an additional 48 hours. Selection for dhfr expressing transfectants was accomplished by replacing the media with DMEM supplemented with 10% dialyzed FBS (Gibco) and 150 μ g/ml L-proline. Colonies were observed after
30 culturing the cells 10-14 days in the selection media.

6.1.2 SELECTION OF METHOTREXATE RESISTANT CELLS

Dihydrofolate reductase (dhfr) amplified cells were derived from the primary transfectants
35 essentially as described (Gasser, C.S. and Schimke,

- 21 -

R.T., 1996, J. Biol. Chem. 261:6938-6946). After expansion, 10^5 cells were seeded onto 100 mm dishes and adapted to increasing concentrations of methotrexate (100 nM; 500 nM; 2,500 nM; 10,000 nM; 20,000 nM). The initial concentration of methotrexate was 100 nM. The plate containing visible colonies was trypsinized and adapted to that concentration of methotrexate for at least two additional 1:5 cell passages. Cells (10^5) were then seeded onto 100 mm dishes in the next highest concentration of methotrexate. The dish containing visible colonies was again trypsinized and adapted in the methotrexate containing medium. Cells were frozen back at various stages of amplification in media containing 40% FBS, 10% dimethyl sulfoxide and 50% DMEM. Methotrexate was not included in the freezing media.

6.1.3 GROWTH INHIBITION ASSAY

Mink lung epithelial cells, Mv 1 Lu (Accession Number CCL-64, American Type Culture Collection), which are extremely sensitive to TGF- β were utilized for the growth inhibition assay. The assay was performed using the thymidine analog 5'-[125 I]-iodo-2'deoxyuridine (125 IdU) to assess DNA synthesis. One unit of activity was defined as the amount required to inhibit 50% incorporation of 125 IdU compared to untreated CCL-64 cells.

To assay transfected cells for secretion of active TGF- β 1/ β 2, serum free supernatants were collected from one 24 hour collection on confluent cultures of cells and dialyzed extensively against 0.2 M acetic acid. Samples were diluted into sterile complete culture medium for assays.

35

SUBSTITUTE SHEET

- 22 -

6.1.4 PEPTIDE SYNTHESIS AND PRODUCTION OF ANTIBODIES

Peptides were synthesized by solid phase techniques on a Beckman 990 instrument, and cleaved from the resin as previously described (Gentry, L.E., et al., 1983, J. Biol. Chem. 258:11219-11228; Gentry, L.E. and Lawton, A., 1986, Virology 152:421-431). Purification was accomplished by preparative high performance liquid chromatography. The composition of the peptides was confirmed by amino acid analysis.

Synthetic peptides were conjugated to bovine gamma-globulin through the cysteine residue. Coupling reactions were performed essentially as described (Gentry and Lawton, 1986, supra). The efficiencies of peptide conjugations ranged from 8 to 26 molecules of peptide covalently attached per molecule of gamma-globulin.

New Zealand white rabbits were primed at three to six sites by combined subcutaneous and intradermal inoculations with the peptide conjugates (100 ug equivalents of peptide) emulsified in Freund's complete adjuvant. Booster inoculations were administered at 2-3 week intervals. Bleedings were taken 7-14 days following the boosts.

Anti-peptide antibodies directed toward peptide sequences within the TGF- β 1 molecule were generated in rabbits using synthetic peptides as immunogens (Gentry et al., 1987, Mol. Cell. Biol. 7:3418-3427). One of the antibodies (anti-TGF- β 1₃₆₉₋₃₈₁) was directed toward epitopes present within the mature form of the TGF- β growth factor. The other two antibodies (anti-TGF- β 1₈₁₋₉₄ and anti-TGF- β 1₂₂₅₋₂₃₆) are precursor-specific and are directed toward peptide sequences present only within the precursor molecule of TGF- β 1.

35

SUBSTITUTE SHEET

- 23 -

6.1.5 IMMUNOBLOTTING

Proteins were fractionated on 7.5%-17.5% gradient SDS-polyacrylamide gels and transferred to unmodified nitrocellulose (0.45 μ m; Schleicher and Schuell) for 1 hour at 24 volts at 4°C (Burnette, W.N., 1981, Anal. Biochem. 112:195-203). Excess binding capacity of the nitrocellulose was blocked by incubation with 2.5% BLOTTO (Johnson, D.A., et al., 1984, Gene Anal. Techn. 1:3-8) in phosphate-buffered saline (PBS) containing 0.2% NP-40. Rabbit anti-serum diluted 1:75 in 2.5% BLOTTO was incubated with the blocked nitrocellulose sheets for 2 hours at room temperature. After washing away excess antibody by five 5-minute washes in 2.5% BLOTTO, the nitrocellulose sheets were incubated with alkaline phosphatase-conjugated Protein A diluted 1:500 in 2.5% BLOTTO. Following a two hour incubation, the nitrocellulose sheets were washed 5 times in PBS (5 minute washes) containing 0.2% NP-40 and developed (Leary et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:4045-4049).

6.1.6 CONSTRUCTION OF PLASMID PROGRAMMING THE SYNTHESIS OF TGF- β 1/ β 2

The plasmid programming the synthesis of the chimeric TGF- β 1/ β 2 protein, p5 β /dhfr, was constructed as follows. pAc β TGF-1, a baculovirus vector derived from pAc373 (Miyamoto et al., 1985, Cell. Biol. 5:2860-2865; Madisen et al., 1987, Virology 158:248-250), which contains the 1.4 Kb PstI-EcoRI coding sequence of TGF- β 1 (Sharples et al., 1987, DNA 6:239-244) cloned into the PstI-EcoRI site of pAc611 (Miyamoto et al., 1985, Cell. Biol. 5:2860-2865; Madisen et al., 1987, Virology 158:248-250), was digested with BamHI and EcoRI and the 375 bp fragment of the TGF- β 1 coding sequence was isolated (Fragment 1). pSV2- β TGF (Gentry et al., 1987, Mol. Cell. Biol.

- 24 -

7:3418-3427) was digested with ApaI and EcoRI and the 3.5 Kb fragment was isolated (Fragment 2).

Complementary synthetic oligonucleotides having the sequences shown below were synthesized on an
 5 Applied Biosystems Oligonucleotide Synthesizer and purified from an acrylamide gel. Phosphates were added with T4 kinase and equimolar amounts of the kinased oligonucleotides were annealed. The annealed double stranded synthetic DNA was then ligated to
 10 fragments '1' and '2' described above. The ligation mixture was used to transform E. coli and 5 β pSV2(Hpa⁻Eco⁺) was isolated.

5' - CAA CAT CTG CAA AGC TCC CGG CAC CGC CGA GCC
 15 CTG GAC ACC AAC TAC TGC TTC AGA AAT GTG CAG
GAT AAT TGC TGC CTA CGT CCG CTT TAC ATT GAT
TTC AAG AGG GAT CTA GGG TGG AAA TG - 3'

5' GAT CCA TTT CCA CCC TAG ATC CCT CTT GAA ATC
 20 AAT GTA AAG CGG ACG TAG GCA GCA ATT ATC CTG
CAC ATT TCT GAA GCA GTA GTT GGT GTC CAG GGC
TCG GCG GTG CCG GGA GCT TTG CAG ATG TTG GGC C - 3'

5 β pSV2(Hpa⁻Eco⁺) was digested with EcoRI, filled
 25 in with Klenow enzyme, digested with HindIII and the 1.4 Kb fragment containing the chimeric TGF- β 1/ β 2 coding sequence was isolated (Fragment 3). 5 β pSV2 was constructed by ligating Fragment 3 into pSV2,neo which had previously been digested with HindIII and HpaI to
 30 eliminate the neo gene.

5 β pSV2 was digested with EcoRI, filled in with Klenow enzyme, digested with NdeI and the 2.6 Kb NdeI-EcoRI (blunt) fragment was isolated and ligated to
 35 7:3718-3727) which had been digested with NdeI and

SUBSTITUTE SHEET

- 25 -

PvuII. The ligation mixture was used to transform E. coli and p5 β /dhfr was isolated. The nucleotide and deduced amino acid sequences of the chimeric TGF- β 1/ β 2 molecule encoded by p5 β /dhfr are shown in FIG. 1.

5

6.2 EXPRESSION OF TGF- β 1/ β 2 IN CHO CELLS

p5 β /dhfr was transfected into CHO cells and single clones were amplified with methotrexate as described in Section 6.1., supra. One such amplified
10 clone, CHO-5 β 41,2.5, was chosen for further characterization.

CHO-5 β 41,2.5 cells were grown to confluence in 2.5 μ M methotrexate. Media was replaced with serum free media and, after 24 hr, was collected and
15 dialyzed for 48 hr against 0.2M acetic acid. Dialyzed, conditioned supernatants were assayed for bioactivity by inhibition of DNA synthesis of CCL-64 cells as described in Section 6.1.3., supra. CHO-5 β 41,2.5 cells secrete approximately 1 mg/L of
20 bioactive chimeric TGF- β 1/ β 2 (FIG. 2).

TGF- β related proteins secreted by these cells were analyzed by immunoblotting using anti-peptide antibodies directed against mature TGF- β 1 as described in Section 6.1.5., supra. FIG. 3 shows that CHO-
25 5 β 41,2.5 cells secrete immunoreactive proteins migrating at 90 to 100 kilodaltons and at 24 kilodaltons when analyzed on SDS-PAGE under nonreducing conditions (FIG. 3, lane 1). The 24 kilodalton band represents the mature TGF- β 1/ β 2 dimer
30 and the 90 to 100 kilodalton protein probably represents mature TGF- β 1/ β 2 disulfide-bonded to precursor sequences (Gentry et al., 1987, Mol. Cell. Biol. 7:3418-3427).

Under reducing conditions (FIG. 3, lane 2), the
35 majority of the proteins migrate at 12 kilodaltons,

- 26 -

representing the mature TGF- β 1/ β 2 monomer. Note the lack of immunoreactive material in the 45 to 55 kilodalton range observed in a similar analysis of recombinant proteins expressed in CHO cells

5 transfected with plasmids encoding the simian TGF- β 1 gene (Gentry et al., 1987, Mol. Cell. Biol. 7:3418-3427) suggesting that chimeric TGF- β 1/ β 2 is proteolytically processed more efficiently than its parent molecule TGF- β 1. In addition, CHO-5 β 41,2.5

10 cells secrete about 2.5 times more bioactive mature product than do CHO cells expressing TGF- β 1 (Gentry et al., 1987, supra). Although the basis for these observations is presently unknown, the secondary structure of the chimeric TGF- β 1/ β 2 precursor may

15 significantly differ from the secondary structure of TGF- β 1, which secondary structure renders the chimeric TGF- β 1/ β 2 subject to molecular processing events of a different intensity or nature. For example, the TGF- β 1/ β 2 precursor may be a more favorable substrate for

20 the factors involved in TGF- β processing. Alternatively, the secondary structural characteristics of TGF- β 1/ β 2 may allow it to interact with other processing factors or pathways not as accessible to TGF- β 1.

25

7. EXAMPLE: GROWTH MODULATION OF VASCULAR
ENDOTHELIAL CELLS BY HYBRID TGF-5 β

Using three distinct bioassays which previously indicated that differential responses are induced by

30 TGF- β 1 and TGF- β 2 (Merwin et al., 1991, Am. J. Path. 138(1):37-51), the biological effects induced by recombinant hybrid TGF- β 1/ β 2 (TGF-5 β) on the proliferation, migration and angiogenesis of large vessel endothelial, smooth muscle and microvascular

35 endothelial cells were examined.

SUBSTITUTE SHEET

- 27 -

7.1 MATERIALS AND METHODS

7.1.1 CELL CULTURE

Bovine aortic smooth muscle cells (BASMCS) were
5 grown from explants of bovine aorta in complete DME
supplemented with 10% FCS as described in Kocher and
Madri, 1989, In Vitro Cell. & Dev. Biol. 25:424-34.
After several days in culture, BASMCS migrate out from
the medial explants. Following the development of
10 confluency, the cells were trypsinized, passaged and
utilized in the growth inhibitory assays described,
infra. These α -smooth muscle, actin positive cells
formed the hill-and-valley pattern typical of cultured
smooth muscle cells and were used between passage 2
15 and 5.

Capillary endothelial cells were isolated and
cultured from rat epididymal fat pads as described in
Madri and Williams, 1983, J. Cell Biol. 97:153-65, and
are hereinafter termed "RFCs". Bovine calf aortic
20 endothelial cells (BAECs) were isolated and cultured
as described in Madri and Furthmayr, 1980, Hum. Path.
11:353-66. Three-dimensional RFC cultures were
composed of acid soluble calf dermis collagen type I
and prepared using the method of Madri et al., 1988,
25 J. Cell Biol. 106:1375-84. To address the possibility
of differences due to the use of two species,
proliferative, migratory and angiogenic studies were
also performed using bovine adrenal cortex
microvascular endothelial cells; the results were
30 equivalent to those obtained with RFCs.

7.1.2 TGF- β FACTORS

Recombinant hybrid TGF- β 1/ β 2 was produced as
described in Section 6, et seq, supra. TGF- β 1 and
35 TGF- β 2 were prepared, respectively, as described in

- 28 -

Assoian et al., 1983, J. Biol. Chem. 258:7155-60, and
in Cheifetz et al., 1987, Cell 48:409-15, and were
obtained from Drs. A. Roberts and M. Sporn at the
Laboratory of Chemoprevention, National Cancer
5 Institute, Bethesda, MD.

7.1.3 MATRIX COMPONENTS

Tissue culture dishes and flasks were coated with
purified bovine type I collagen (Madri and Furthmayr,
10 1980, Hum. Path. 11:353-66) at a concentration of 12.5
 $\mu\text{g/ml}$.

7.1.4 PROLIFERATION INHIBITION ASSAY

Collagen type I-coated dishes were washed in PBS
15 before the addition of cell suspensions (1.4×10^4
cells/dish). After 6 h, the "initial" number of cells
on the substrate was determined. At this time point,
fresh medium with or without TGF- β s was added to the
cultures. Medium and TGF- β s were replaced once again
20 on day 3. Cell numbers were determined by lifting the
cells off the culture dishes with trypsin/EDTA and
counting quadruplicate samples using a Coulter counter
(Coulter Electronics, Inc., Hialeah, FL). The mean
number of cells per dish for each TGF- β addition was
25 then calculated.

7.1.5 CELL MIGRATION ASSAYS

Stimulus for cell migration was accomplished by
releasing confluent cultures from contact inhibition
30 using a stainless steel "fence" device as previously
described (Pratt et al., 1984, Am. J. Path. 117:349-
54). Once confluency had been achieved in the center
wells of the fences (~6 h), migration was induced by
removing the fences, and cells were thereafter
35 observed migrating outward in a radial fashion.

SUBSTITUTE SHEET

- 29 -

Cultures were fed once again on day 3 with control or TGF- β -supplemented media. After 6 days, the cultures were washed with PBS, fixed with 10% neutral buffered formalin and stained with Harris hematoxylin. Net
5 increase in surface area covered was assessed using an overhead projector, and areas were calculated utilizing a computerized graphics tablet and "MacMeasure" software (Yale Shareware, Yale Univeristy, New Haven, CT).

10

7.2 RESULTS

The majority of published reports indicate that the TGF- β 1 and TGF- β 2 isoforms are equipotent in vitro. However, recent reports indicate that these
15 isoforms are not functionally interchangeable, since they elicit dissimilar effects and exhibit different spatial and temporal localizations (See, for example, Ohto et al., 1987, Nature 329:539-41; Rosa et al., 1988, Science 239:783-85; and Danielpour et al., 1989,
20 J. Cell Physiol. 138:79-86). TGF- β 1 is reportedly more effective than TGF- β 2 in inhibiting DNA synthesis in endothelial cells (Jennings, et al., 1988, J. Cell. Physiol. 137:167-72).

A recent report establishes that TGF- β 1 and TGF-
25 β 2 isoforms elicit differential responses in proliferation assays using three vascular cell types (Merwin et al., 1991, Am J. Path. 138(1):37-51). Therefore, investigating the effects of TGF-5 β on endothelial cells seemed ideal for determining whether
30 the TGF- β 1/TGF- β 2 hybrid (TGF-5 β) would evoke responses similar to TGF- β 1 or to TGF- β 2. The results indicated that TGF-5 β mimicked TGF- β 1 in all three proliferation assays examined, while TGF- β 2 displayed unique properties.

35

- 30 -

Both TGF- β 1 and TGF- β 5 inhibited BAEC proliferation by more than 70% (+/-1.5%) at the optimum concentration of 0.5 ng/ml (FIG. 4A). In contrast, TGF- β 2 was only able to evoke inhibition of about 20% (+/-2.5%). When using BASMCs, all three growth factors exhibited similar inhibitory activities (FIG. 4B). Microvascular endothelial cells were growth inhibited as much as 70% (+/- 4.0%) by both TGF- β 1 and TGF- β 5 at concentrations of 0.5 ng/ml (FIG. 4C). At equivalent concentration, however, TGF- β 2 was only able to mount a 37% (+/- 8%) inhibition; however, with a 10-fold increase in concentration, TGF- β 2 was able to evoke a similar response.

Similarly, hybrid TGF- β 5 exerted a cell migration response equivalent to that induced by TGF- β 1. The results presented in FIG. 5 show that BAECs are inhibited by both TGF- β 5 and TGF- β 1, while BASMCs are growth-stimulated by both factors. In contrast, TGF- β 2 had no effect on the migration of either cell type.

The above results may help to explain vascular response to injury. Upon denudation (i.e., following angioplasty) of the endothelial barrier, platelets adhere and aggregate to the newly exposed subendothelial extracellular matrix and release a variety of molecules. In this regard, one of the major factors released by platelets is TGF- β 1. With a marked increase in the local concentration of TGF- β 1, endothelial cells may be inhibited from migrating to affect a rapid re-endothelialization of the injury while at the same time, smooth muscle cell migration toward an increased factor gradient may be stimulated, thereby establishing an ideal opportunity for perpetuating the expansion of the medial compartment of the vessel wall and continued occlusion of the vascular lumen.

SUBSTITUTE SHEET

- 31 -

While angiogenesis is an important and necessary response during embryogenesis and tissue repair, it is an undesirable phenomenon in the context of solid tumor growth. Therefore, understanding the enhancement of neovascularization is of paramount concern. To investigate the TGF- β -induced angiogenic response in microvascular endothelial cells, RFCs were grown in three-dimensional collagen cultures for 4 days, either in the presence or absence of TGF- β isoforms. All three isoforms were able to stimulate RFCs to mount a neovascularization response. This endothelial "activation" was previously defined by extensive EM analysis (Merwin et al., 1990, J. Cell. Physiol. 142:117-29) which revealed the formation of branching tubular structures, cell-cell junctional complexes, metabolic stimulation (increased numbers of ribosomes and engorged ER), cellular polarity, deposition and organization of extracellular matrix proteins and lumen formation.

FIG. 6A shows control cultures with no exogenous growth factor. Cells remain independent of one another and lack tubular structures, while treatment with TGF- β 1 (FIG. 6B) reveals complex, tube-like formations. TGF- β 2 (FIG. 6C) was able to initiate a modest angiogenic response. However, as with RFC proliferation studies, an increase in TGF- β 2 concentration from 0.5 to 5.0 ng/ml was necessary for the establishment of complex tubular structures. TGF- β 5 mimicked TGF-1, with tube formation initiated with as little as 0.05 ng/ml (FIG. 6D), and optimal neovascularization achieved at a concentration of 0.5 ng/ml (FIG. 6E). A slight inhibition of the angiogenic response was noted at the highest concentration used, 5.0 ng/ml (FIG. 6F).

35

- 32 -

In summary, TGF- β 2 mimics TGF- β 1 in inhibiting proliferation of low density monolayer micro and large vessel endothelial cell cultures by about 70% and by about 45% on BASMCs. In contrast, an equivalent concentration of TGF- β 2 is ineffective with BAECs and equivalent on BASMCs. Moreover, a 10-fold increase in TGF- β 2 concentration is required to elicit a similar response with RFCs. When using a culture which begins with a tight, confluent monolayer, response induced by the isoforms differ. In particular, both TGF- β 1 and TGF- β 2 induce equivalent levels of BASMC migration enhancement and BAEC migration inhibition, while TGF- β 2 does not influence the migration of either cell type. Finally, in microvascular endothelial cells which respond to injury in vivo by neovascularization, all three TGF- β s were able to stimulate angiogenesis in vitro. However, a 10-fold increase in TGF- β 2 concentration was necessary to match the level of response induced by TGF- β 1 and TGF- β 5.

8. DEPOSIT OF MICROORGANISMS

The following transfectant has been deposited with the American Type Culture Collection, Rockville, MD, and has been assigned the listed accession number.

<u>Transfectant</u>	<u>Plasmid</u>	<u>Accession No.</u>
CHO-5 β 41,2.5 CL 5	p5 β /dhfr	CRL 9959

The present invention is not to be limited in scope by the cell line deposited or the embodiments disclosed herein which are intended as single illustrations of one aspect of the invention and any which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and

described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

It is also to be understood that all base pair and amino acid residue numbers and
5 sizes given for nucleotides and peptides are approximate and used for the purposes of description.

Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives or components or integers.



The claims defining the invention are as follows:

1. A chimeric transforming growth factor $\beta 1/\beta 2$.
2. A chimeric transforming growth factor $\beta 1/\beta 2$ consisting of the amino acid sequence as given in figure 1A - 1D.
- 5 3. A chimeric transforming growth factor 5β consisting of amino acids 279 - 390 as given in figure 1C- 1D.
4. A pharmaceutical composition comprising the chimeric transforming growth factor 5β consisting of amino acids 279 - 390 as given in figure 1C - 1D.
5. Use of the pharmaceutical composition according to claim 2 in inhibiting the
10 proliferation of vascular endothelial cells.
6. Use of the pharmaceutical composition according to claim 2 in inducing smooth muscle cell migration.
7. A pharmaceutical composition comprising an antibody to chimeric transforming growth factor 5β consisting of amino acids 279 - 390 as given in figure 1C - 1D, for use
15 in inhibiting microvascular cell neovascularisation.

DATED: 16 April, 1996

PHILLIPS ORMONDE & FITZPATRICK

Attorneys for:

20 BRISTOL-MYERS SQUIBB COMPANY

3
A



SIMIAN																				
HUMAN																				
	-261 AGGGGATCTGTGGCAGGTCGGAGA---AAGA -234																			
	CTCC..C...CCA...A..CCCT.TTC....																			
SIMIAN	TC---CGTCTCCTGGTACCAGATCTCGCCCATCTAGGTTATTTCCGTGGGATACTGAGACACCCCCGGTCCAAGCCTCC -158																			
HUMAN	C.ACC.AC..T.....G.....																			
SIMIAN	CCTCCACCACTGCGCCCTTCTCCCTGAGGA-CCTCAACTTTCCCTCGAGGCCCTCCTACCTTTTCCCGGGGGACCCCA -80																			
HUMAN	G.....G.....G.....A.....																			
SIMIAN	GCCCTGCAGGGGCGGGCCCTCCCCACCAAAGTAGCCCTGTTTCGCGCTCTCGGCAGTGCCGGGGGGCGCCGCCTCCCCC -1																			
HUMAN	C..C.....																			
	10										20									
SIMIAN	Met	Pro	Pro	Ser	Gly	Leu	Arg	Leu	Leu	Pro	Leu	Leu	Leu	Pro	Leu	Leu	Trp	Leu	Leu	Val
HUMAN	ATG	CCG	CCC	TCC	GGG	CTG	CGG	CTG	CTG	CCG	CTG	CTG	CTA	CCA	CTG	CTG	TGG	CTA	CTG	GTG
	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
	30										40									
SIMIAN	Leu	Thr	Pro	Gly	Pro	Pro	Ala	Ala	Gly	Leu	Ser	Thr	Cys	Lys	Thr	Ile	Asp	Met	Glu	Leu
HUMAN	CTG	ACG	CCT	AGC	CGG	CCG	GCC	GCA	GGA	CTA	TCC	ACC	TGC	AAG	ACT	ATC	GAC	ATG	GAG	CTG
	...	...	...	G..	.C.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
	50										60									
SIMIAN	Val	Lys	Arg	Lys	Arg	Ile	Glu	Thr	Ile	Arg	Gly	Gln	Ile	Leu	Ser	Lys	Leu	Arg	Leu	Ala
HUMAN	GTG	AAG	CGG	AAG	CGC	ATC	GAG	ACC	ATC	CGC	GGC	CAG	ATC	CTG	TCC	AAG	CTG	CGG	CTC	GCC
	...	...	...	...	...	...	...	G..	...	...	...	...	...	...	...	...	...	...	...	...
	70										80									
SIMIAN	Ser	Pro	Pro	Ser	Gln	Gly	Glu	Val	Pro	Pro	Gly	Pro	Leu	Pro	Glu	Ala	Val	Leu	Ala	Leu
HUMAN	AGC	CCC	CCG	AGC	CAG	GGG	GAG	GTG	CCG	CCC	GGC	CCG	CTG	CCC	GAG	GCC	GTG	CTC	GCC	CTG
	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...

1/12

18878/92

FIG.1A

SUBSTITUTION	SIMIAN HUMAN	Tyr	Asn	Ser	Thr	Arg	Asp	Arg	Val	Ala	Gly	Glu	Ser	Ala	Glu	Pro	Glu	Pro	Glu	Pro	Glu	300
		TAC	AAC	AGC	ACC	CGC	GAC	CGG	GTG	GCC	GGG	GAG	AGT	GCG	GAG	CCG	GAG	CCC	GAA	CCG	GAG	
		...	...	...	...	...	...	...	...	...	...	...	...	...A	...A	...	...	...	...G	...T	...	
											90										100	
SUBSTITUTION	SIMIAN HUMAN	Ala	Asp	Tyr	Tyr	Ala	Lys	Glu	Val	Thr	Arg	Val	Leu	Met	Val	Glu	Thr	His	Asn	Glu	Ile	360
		GCC	GAC	TAC	TAC	GCC	AAG	GAG	GTC	ACC	CGC	GTG	CTA	ATG	GTG	GAA	ACC	CAC	AAC	GAA	ATC	
		...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
											110										120	
SUBSTITUTION	SIMIAN HUMAN	Tyr	Asp	Lys	Phe	Lys	Gln	Ser	Thr	His	Ser	Ile	Tyr	Met	Phe	Phe	Asn	Thr	Ser	Glu	Leu	420
		TAT	GAC	AAG	TTC	AAG	CAG	AGC	ACA	CAC	AGC	ATA	TAT	ATG	TTC	TTC	AAC	ACA	TCA	GAG	CTC	
		...	...	...	...	...	...	...T	...	...	...	...	...	...	...	...	...	...	...	...	...	
											130										140	
SUBSTITUTION	SIMIAN HUMAN	Arg	Glu	Ala	Val	Pro	Glu	Pro	Val	Leu	Leu	Ser	Arg	Ala	Glu	Leu	Arg	Leu	Leu	---	Arg	477
		CGA	GAA	GCA	GTA	CCT	GAA	CCT	GTG	TTG	CTC	TCC	CGG	GCA	GAG	CTG	CGT	CTG	CTG	---	AGG	
		...	...	...G	...	...	...	...C	...	...	...	...	...	...	...	...	...	...	...	AGG	...	
											150									Arg		
SUBSTITUTION	SIMIAN HUMAN	Leu	Lys	Leu	Lys	Val	Glu	Gln	His	Val	Glu	Leu	Tyr	Gln	Lys	Tyr	Ser	Asn	Asn	Ser	Trp	537
		CTC	AAG	TTA	AAA	GTG	GAG	CAG	CAT	GTG	GAG	CTG	TAC	CAG	AAA	TAC	AGC	AAC	AAT	TCC	TGG	
		...	...	...	...	...	...	...	...C	...	...	...	...	...	...	...	...	...	...	...	...	
											160											
SUBSTITUTION	SIMIAN HUMAN	Arg	Tyr	Leu	Ser	Asn	Arg	Leu	Leu	Ala	Pro	Ser	Asn	Ser	Pro	Glu	Trp	Leu	Ser	Phe	Asp	597
		CGA	TAC	CTC	AGC	AAC	CGG	CTG	CTG	GCG	CCC	AGC	AAC	TCG	CCG	GAG	TGG	TTG	TCT	TTT	GAT	
		...	...	...	...	...	...	...	...	...A	...	...	G...	...	...A	...	...	...A	...	...	...	
											180											

2/12

18878/92

FIG.1B

SIMIAN HUMAN	200	Val	Thr	Gly	Val	Val	Arg	Gln	Trp	Leu	Ser	Arg	Gly	Gly	Glu	Ile	Glu	Gly	Phe	Arg	Leu	657
		GTC	ACC	GGA	GTT	GTG	CGG	CAG	TGG	TTG	AGC	CGC	GGA	GGG	GAA	ATT	GAG	GGC	TTT	CGC	CTT	
		...	...	...	...	...	...	...	...	...	...	..T	...	...	...	...	...	...	...	...	...	
SIMIAN HUMAN	220	Ser	Ala	His	Cys	Ser	Cys	Asp	Ser	Lys	Asp	Asn	Thr	Leu	Gln	Val	Asp	Ile	Asn	Gly	Phe	717
		AGC	GCC	CAC	TGC	TCC	TGT	GAC	AGC	AAA	GAT	AAC	ACA	CTG	CAA	GTG	GAC	ATC	AAC	GGG	TTC	
		...	...	...	...	...	...	...	...	.GG	...	...	...	...	...	...	...	...	...	...	...	
SIMIAN HUMAN	240	Thr	Thr	Gly	Arg	Arg	Gly	Asp	Leu	Ala	Thr	Ile	His	Gly	Met	Asn	Arg	Pro	Phe	Leu	Leu	777
		ACT	ACC	GGC	CGC	CGA	GGT	GAC	CTG	GCC	ACA	ATT	CAT	GGC	ATG	AAC	CGG	CCT	TTC	CTG	CTT	
		...	...	...	...	...	...	...	...	...	..C	...	...	...	...	...	...	...	...	...	...	
SIMIAN HUMAN	260	Leu	Met	Ala	Thr	Pro	Leu	Glu	Arg	Ala	Gln	His	Leu	Gln	Ser	Ser	Arg	His	Arg	Arg	Ala	837
		CTC	ATG	GCC	ACC	CCA	CTG	GAG	AGG	GCC	CAA	CAT	CTG	CAA	AGC	TCC	CGG	CAC	CGC	CGA	GCC	
		...	...	...	...	..G	...	...	...	...	..G	...	...	...	...	...	...	...	...	...	...	
SIMIAN HUMAN	280	Leu	Asp	Thr	Asn	Tyr	Cys	Phe	Arg	Asn	Val	Gln	Asp	Asn	Cys	Cys	Leu	Arg	Pro	Leu	Tyr	897
		CTG	GAC	ACC	AAC	TAC	TGC	TTC	AGA	AAT	GTG	CAG	GAT	AAT	TGC	TGC	CTA	CGT	CCG	CTT	TAC	
		...	...	...	...	..T	...	...	...	...	...	...	...	...	...	...	...	...	...	...	..C	
SIMIAN HUMAN	300	Ile	Asp	Phe	Lys	Arg	Asp	Leu	Gly	Trp	Lys	Trp	Ile	His	Glu	Pro	Lys	Gly	Tyr	His	Ala	957
		ATT	GAC	TTC	AAG	AGG	GAC	CTC	GGC	TGG	AAG	TGG	ATC	CAC	GAG	CCC	AAG	GGC	TAC	CAT	GCC	
		...	..T	...	...	...	..T	..A	..G	...	..A	...	...	...	...	...	...	...	...	...	...	

FIG.1C

	320		330	
SIMIAN	Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val	1017		
HUMAN	AAC TTC TGC CTG GGG CCC TGT CCC TAC ATT TGG AGC CTG GAC ACG CAG TAC AGC AAG GTC			
	CC			
	340		350	
SIMIAN	Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys Val Pro Gln	1077		
HUMAN	CTG GCC CTG TAC AAC CAG CAT AAC CCG GGC GCC TCG GCG GCG CCG TGC TGC GTG CCG CAG			
				
	360		370	
SIMIAN	Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg Lys Pro Lys Val Glu Gln Leu	1137		
HUMAN	GCG CTG GAG CCA CTG CCC ATC GTG TAC TAC GTG GGC CGC AAG CCC AAG GTG GAG CAG CTG			
	G			
	380		390	
SIMIAN	Ser Asn Met Ile Val Arg Ser Cys Lys Cys Ser			
HUMAN	TCC AAC ATG ATC GTG CGC TCC GTC AAA TGC AGC	4204		
	G			
			TGA GGCCCCGCCCCGCCCCGCCCCACCCCGGCAG	
			T.....G.....	
SIMIAN	GCCCGGCCCCGCCCCACCCACCCCGCTGTCTTGCCCTTGCGGGCTGTATTTAAGGACACCCGTGCCCCAAGCCCACC	1283		
HUMAN	A G G C A			
SIMIAN	TGGGGCCCCATTAAAGA	1300		
HUMAN				

FIG. 1D

4/12

18878/92

5/12

FIG. 2A






FIG. 2B



SUBSTITUTE SHEET

6/12

FIG. 3



7/12




FIG. 4A

8/12




FIG. 4B

9/12




FIG. 4C

10/12




FIG. 5

11 / 12



FIG. 6A



FIG. 6B




FIG. 6C

12/12




FIG. 6D



FIG. 6E




FIG. 6F

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/01993

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): A61K 37/24; C07K 13/00 US CL : 514/12; 530/399		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	514/12; 530/399	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁵		
DIALOG, MEDLINE, APS, PROTEIN SEQUENCE DATABASES (PIR, SWISS-PROT)		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category*	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
A	US, A, 4,742,003 (Derynck, et al.) 03 MAY 1988.	1-3
A	J. BIOL. CHEM., Volume 265, issued 05 November 1990, R. Lafyatis, "Structural and Functional Characterization of the Transforming Growth Factor beta 3 Promotor. A cAMP-Responsive Element Regulates Basal and Induced Transcription," pages 19128-36.	1-3
A,E	CLINICAL RESEARCH, volume 40, APRIL 1992, A.B. Kulkarni, "Mouse Chimeras With A Disrupted Transforming Growth-Beta-1 Gene Obtained By Gene Targeting", page 295, N2.	1-3
* Special categories of cited documents:¹⁵ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art .. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
22 June 1992	30 JUN 1992	
International Searching Authority ¹	Signature of Authorized Officer ²⁰	
ISA/US	SHELLY J. GUEST 